Strategies to Remove Pre-Existing AAV Antibodies: IgG Enzymatic Degradation vs FcRn Inhibition. Presented by Yash Shah, PhD, ...

The University at Albany hosted its third annual Showcase Day, recognizing the creative and innovative work of students ...

Forge Biologics ("Forge"), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, ...

These posters highlight key data supporting the rationale for the Phase 1b program in biomarker-selected cancers as a single agent, and in combination with market leading therapies to overcome ...

Sonoma Biotherapeutics Announces Oral and Poster Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Sonoma Biotherapeutics, Inc., a clinical-stage ...

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the ...

FORE Biotherapeutics has announced that its plixorafenib abstract has been selected for poster presentation at the highly ...

Seven Northwestern undergraduate students took home awards for their research at the Chicago Area Undergraduate Research ...

Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced its slate of seven scientific presentations, three oral and four in poster form, that have been accepted for the 28th Annual ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened ...

The poster presentations will include preclinical safety and efficacy results, highlighting STRO-004's significant anti-tumor activity and safety profile. Sutro's CEO, Jane Chung, expressed ...